A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
REVVITY, INC.
RVTY
$12.9B
Mkt Cap
$110.47
-2.39%
REVVITY, INC. (RVTY) has a current P/E ratio of 53.4, compared to its historical median P/E of 29.8. The stock is currently considered Expensive based on its historical valuation range.
REVVITY, INC. (RVTY) has a 5-year average return on invested capital (ROIC) of 6.6%. This is below average and may indicate limited pricing power.
REVVITY, INC. (RVTY) has a market capitalization of $12.3B. It is classified as a large-cap stock.
Yes, REVVITY, INC. (RVTY) pays a dividend with a trailing twelve-month yield of 0.26%. The company also returns capital through share buybacks, with a buyback yield of 6.11%.
Based on historical P/E analysis, REVVITY, INC. (RVTY) appears expensive. The current P/E of 53.4 is 79% above its historical median of 29.8. The estimated fair value CAGR (P/E method) is 6.0%.
REVVITY, INC. (RVTY) operates in the Laboratory Analytical Instruments industry, within the Technology sector.
REVVITY, INC. (RVTY) reported annual revenue of $2.9 billion in its most recent fiscal year, based on SEC EDGAR filings.
Revvity is a leading provider of health science solutions, technologies, expertise and services that enable workflows from discovery to development and diagnosis to cure, operating in more than 160 countries with approximately 11,000 employees. The company operates two core segments: Life Sciences, which provides a comprehensive portfolio of reagents, instruments, and software that facilitate drug discovery and development for pharmaceutical, biotech, contract research organizations, and academic institutions; and Diagnostics, which includes reproductive health and immunodiagnostics businesses serving clinical and research markets. The Life Sciences segment offers over 35,000 SKUs of reagents including antibodies, assay kits, and cell lines, alongside instruments such as high-content screening systems, plate readers, and in vivo imaging platforms, complemented by software solutions like Harmony and Signals that drive end-to-end workflow optimization. The Diagnostics segment generates revenue through newborn screening, reproductive health testing, and immunodiagnostic assays, with the company demonstrating particular strength in translational multi-omics technologies, biomarker identification, and AI-enabled informatics. The business model is characterized by recurring consumables revenue from reagents and assays paired with capital equipment sales and software subscriptions, creating a balanced mix of transactional and recurring revenue streams that serve global pharmaceutical, biotech, academic, and government customers across the Americas, Europe, and Asia-Pacific regions.
【Strategic portfolio refinement underway】 Management is executing a transformational strategy to divest the lower-growth, lower-margin immunodiagnostics business in China by year-end 2026, which is expected to improve organic growth by approximately 100 basis points and enhance operating margins by approximately 30 basis points on a pro forma basis. The company anticipates continued strong performance in Life Sciences, particularly in China where the right products and market positioning are driving meaningful growth, while Diagnostics is expected to benefit from sustained momentum in reproductive health and newborn screening despite challenging global birth rate trends. Management expects AI-driven acceleration in scientific discovery to generate significant future demand for consumables, instruments, and software as customers utilize these offerings to validate new therapeutic compounds and biological targets, positioning the company well for robust margin expansion in the first half of 2027 as cost efficiency initiatives anniversary. The company remains prudent in near-term assumptions pending more sustainable signs of concrete improvement in pharma and academic customer spending, though recent signs of stronger biopharma funding and M&A activity suggest potential for market recovery beyond current guidance.
| Metric | Target | Period |
|---|---|---|
| Total Revenue | $2.81 billion–$2.84 billion | FY2026 |
| Organic Growth | 3%–4% | FY2026 |
| Adjusted Operating Margin | 28.4% | FY2026 |
| Adjusted Earnings Per Share | $5.20–$5.30 | FY2026 |
Total Revenue (FY2026): “our updated 2026 total revenue outlook, which now calls for $2.81 billion-$2.84 billion in total revenue this year”
Organic Growth (FY2026): “we are now expecting our pro forma organic growth this year to be in the 3%-4% range”
Adjusted Operating Margin (FY2026): “adjusted operating margins of 28.4%”
Adjusted Earnings Per Share (FY2026): “adjusted earnings per share of $5.20-$5.30”
Generated solely from the company's own reports listed below — not from third-party data. Hallucination risk is low. · Sources: 10-K, Q4 FY2025 Earnings Call, Q3 FY2025 Earnings Call, Q2 FY2025 Earnings Call, Q1 FY2025 Earnings Call
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.9B | 2.9B | 2.8B | 2.8B | 3.8B | 3.8B |
| Net Income | 240M | 241M | 270M | 693M | 943M | 728M |
| EPS | $2.11 | $2.07 | $2.20 | $5.55 | $8.08 | $6.49 |
| Free Cash Flow | 493M | 509M | 542M | 9.9M | 1.3B | 829M |
| ROIC | 3.4% | 3.3% | 3.1% | 2.7% | 11.3% | 12.8% |
| Gross Margin | - | - | - | 72.3% | 63.6% | 55.8% |
| Debt/Equity | 0.45 | 0.46 | 0.43 | 0.51 | 0.70 | 0.53 |
| Dividends/Share | $0.29 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 |
| Operating Income | 360M | 357M | 347M | 301M | 1.3B | 867M |
| Operating Margin | 12.4% | 12.5% | 12.6% | 10.9% | 32.9% | 22.9% |
| ROE | 3.3% | 3.2% | 3.5% | 9.2% | 17.3% | 19.5% |
| Shares Outstanding | 112M | 117M | 123M | 125M | 117M | 112M |
| Metric | 2015 | 2020 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 2.2B | 2.3B | 2.1B | 2.3B | 2.8B | 2.9B | 3.8B | 3.8B | 3.8B | 2.8B | 2.8B | 2.9B | 2.9B |
| Gross Margin | 44.9% | 45.3% | 45.8% | 47.6% | 48.3% | 48.4% | 55.8% | 55.8% | 63.6% | 72.3% | N/A | N/A | N/A |
| R&D | 108M | 126M | 113M | 139M | 194M | 189M | 205M | 146M | 200M | 217M | 197M | 216M | 220M |
| SG&A | 648M | 599M | 587M | 626M | 812M | 815M | 918M | 716M | 975M | 1.0B | 994M | 992M | 996M |
| EBIT | 165M | 286M | 251M | 296M | 324M | 362M | 979M | 867M | 1.3B | 301M | 347M | 357M | 360M |
| Op. Margin | 7.4% | 12.6% | 11.9% | 13.1% | 11.7% | 12.6% | 25.9% | 22.9% | 32.9% | 10.9% | 12.6% | 12.5% | 12.4% |
| Net Income | 158M | 212M | 212M | 293M | 238M | 228M | 728M | 728M | 943M | 693M | 270M | 241M | 240M |
| Net Margin | 7.1% | 9.4% | 10.1% | 13.0% | 8.6% | 7.9% | 19.2% | 19.2% | 24.6% | 25.2% | 9.8% | 8.4% | 8.3% |
| Non-Recurring | 13M | 14M | 14M | 13M | 11M | 29M | 16M | 16M | 18M | 27M | 40M | 61M | 61M |
| Returns on Capital | |||||||||||||
| ROIC | 5.8% | 8.6% | 7.9% | 4.9% | 6.9% | 7.6% | 16.3% | 12.8% | 11.3% | 2.7% | 3.1% | 3.3% | 3.4% |
| ROE | 7.8% | 10.2% | 10.1% | 12.7% | 9.4% | 8.4% | 22.2% | 19.5% | 17.3% | 9.2% | 3.5% | 3.2% | 3.3% |
| ROA | 3.9% | 5.1% | 5.1% | 5.7% | 3.9% | 3.6% | 10.0% | 9.1% | 8.2% | 4.9% | 2.1% | 2.0% | 2.0% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 282M | 287M | 287M | 288M | 311M | 363M | 892M | 892M | 1.4B | 91M | 628M | 583M | 570M |
| Free Cash Flow | 254M | 257M | 259M | 249M | 218M | 287M | 815M | 829M | 1.3B | 9.9M | 542M | 509M | 493M |
| Owner Earnings | 157M | 157M | 164M | 158M | 102M | 118M | 617M | 664M | 1.1B | -382M | 163M | 155M | 133M |
| CapEx | 27M | 30M | 28M | 39M | 93M | 76M | 78M | 64M | 86M | 81M | 87M | 74M | 77M |
| Maint. CapEx | 110M | 112M | 105M | 105M | 181M | 214M | 247M | 202M | 311M | 432M | 428M | 405M | 413M |
| Growth CapEx | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 110M | 112M | 105M | 105M | 181M | 214M | 247M | 202M | 311M | 432M | 428M | 405M | 413M |
| CapEx/OCF | 10.3% | 10.3% | 9.8% | 13.6% | 30.0% | 21.0% | 8.7% | 8.7% | 6.1% | 12.6% | 13.8% | 12.6% | 13.6% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 32M | 32M | 32M | 31M | 31M | 31M | 31M | 31M | 32M | 35M | 34M | 33M | 32M |
| Dividend Yield | 0.7% | N/A | 0.6% | 0.4% | 0.4% | 0.3% | N/A | 0.2% | 0.2% | 0.2% | 0.3% | 0.3% | 0.3% |
| Share Buybacks | 66M | 76M | 76M | 3.8M | 57M | 6.3M | 6.9M | 6.9M | 73M | 389M | 370M | 821M | 754M |
| Buyback Yield | 1.4% | 0.0% | 1.3% | 0.0% | 0.7% | 0.1% | 0.0% | 0.0% | 0.5% | 0.6% | 2.7% | 7.3% | 6.1% |
| Stock-Based Comp | 14M | 18M | 17M | 25M | 29M | 32M | 29M | 27M | 30M | 41M | 38M | 23M | 24M |
| Debt Repayment | 13M | 0 | 1.1M | 2.8M | 28M | 15M | 0 | 0 | 31M | 15K | 0 | 2.5M | 2.5M |
| Balance Sheet | |||||||||||||
| Net Debt | 870M | 774M | 774M | 1.8B | 1.7B | 2.1B | 1.2B | 1.6B | 4.4B | 2.4B | 2.1B | 2.4B | 2.3B |
| Cash & Equiv. | 175M | 238M | 238M | 202M | 163M | 192M | 402M | 387M | 603M | 913M | 1.2B | 920M | 860M |
| Long-Term Debt | 1.0B | 1.0B | 1.0B | 1.8B | 1.9B | 2.1B | 1.6B | 1.6B | 5.0B | 3.2B | 3.2B | 2.6B | 2.6B |
| Debt/Equity | 0.51 | 0.48 | 0.48 | 0.80 | 0.73 | 0.80 | 0.43 | 0.53 | 0.70 | 0.51 | 0.43 | 0.46 | 0.45 |
| Interest Coverage | 4.5 | 7.5 | 6.6 | 6.7 | 4.8 | 5.7 | 19.7 | 17.4 | 699.1 | 3.0 | 3.6 | 3.9 | 175.4 |
| Equity | 2.0B | 2.1B | 2.1B | 2.5B | 2.6B | 2.8B | 3.7B | 3.7B | 7.1B | 7.9B | 7.7B | 7.3B | 7.2B |
| Total Assets | 4.1B | 4.2B | 4.2B | 6.1B | 6.0B | 6.5B | 8.0B | 8.0B | 15.0B | 13.6B | 12.4B | 12.2B | 12.0B |
| Total Liabilities | 2.1B | 2.1B | 2.1B | 3.6B | 3.4B | 3.7B | 4.2B | 4.2B | 7.9B | 5.7B | 4.7B | 4.9B | 4.8B |
| Intangibles | 490M | 2.3B | 486M | 1.3B | 1.2B | 1.3B | 3.4B | 1.4B | 3.8B | 3.0B | 2.6B | 2.3B | 2.3B |
| Retained Earnings | 1.8B | 2.0B | 2.0B | 2.4B | 2.6B | 2.8B | 3.5B | 3.5B | 4.4B | 5.6B | 5.8B | 6.1B | 6.1B |
| Working Capital | 471M | 472M | 472M | 249M | 463M | 612M | 587M | 587M | 1.2B | 1.6B | 1.7B | 909M | 890M |
| Current Assets | 1.1B | 1.0B | 1.0B | 1.2B | 1.2B | 1.4B | 2.2B | 2.2B | 2.4B | 3.0B | 2.3B | 2.2B | 2.1B |
| Current Liabilities | 597M | 561M | 561M | 951M | 772M | 763M | 1.7B | 1.7B | 1.2B | 1.5B | 653M | 1.3B | 1.2B |
| Per Share Data | |||||||||||||
| EPS | 1.39 | 1.87 | 1.87 | 2.64 | 2.13 | 2.04 | 6.49 | 6.49 | 8.08 | 5.55 | 2.20 | 2.07 | 2.11 |
| Owner EPS | 1.38 | 1.39 | 1.45 | 1.43 | 0.91 | 1.06 | 5.50 | 5.92 | 9.16 | -3.06 | 1.32 | 1.33 | 1.19 |
| Book Value | 17.99 | 18.58 | 18.58 | 22.58 | 23.14 | 25.23 | 33.31 | 33.31 | 61.18 | 63.04 | 62.38 | 62.22 | 64.34 |
| Cash Flow/Share | 2.48 | 2.53 | 2.53 | 2.60 | 2.78 | 3.26 | 7.95 | 7.95 | 12.09 | 0.73 | 5.11 | 5.00 | 5.85 |
| Dividends/Share | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.28 | 0.29 |
| Shares Out. | 113.5M | 113.6M | 113.6M | 110.8M | 111.7M | 111.5M | 112.2M | 112.2M | 116.7M | 124.9M | 122.9M | 116.5M | 111.6M |
| Valuation | |||||||||||||
| P/E Ratio | 30.5 | N/A | 27.2 | 27.2 | 35.6 | 46.9 | N/A | 29.8 | 16.9 | 24.5 | 50.7 | 46.7 | 52.3 |
| P/FCF | 18.9 | N/A | 22.3 | 31.9 | 38.9 | 37.1 | N/A | 26.2 | 12.1 | N/A | 25.3 | 22.1 | 25.0 |
| EV/EBIT | 27.0 | N/A | 25.2 | 31.6 | 31.1 | 34.2 | N/A | 23.8 | 15.7 | 22.8 | 41.9 | 37.1 | 40.7 |
| Price/Book | 2.4 | N/A | 2.7 | 3.2 | 3.3 | 3.8 | N/A | 5.8 | 2.2 | 1.8 | 1.8 | 1.6 | 1.7 |
| Price/Sales | 6.9 | N/A | 8.1 | 3.1 | 3.2 | 3.4 | N/A | 4.7 | 4.6 | 4.5 | 5.0 | 4.0 | 4.2 |
| FCF Yield | 5.3% | N/A | 4.5% | 3.1% | 2.6% | 2.7% | N/A | 3.8% | 8.3% | 0.1% | 3.9% | 4.5% | 4.0% |
| Market Cap | 4.8B | 0 | 5.8B | 8.0B | 8.5B | 10.7B | 0 | 21.7B | 16.0B | 13.9B | 13.7B | 11.3B | 12.3B |
| Avg. Price | 42.60 | 0.00 | 50.42 | 62.28 | 79.06 | 88.39 | 0.00 | 156.85 | 150.06 | 116.54 | 111.51 | 98.81 | 110.47 |
| Year-End Price | 42.46 | N/A | 50.85 | 71.86 | 75.91 | 95.62 | N/A | 193.39 | 136.94 | 110.11 | 111.61 | 96.69 | 110.47 |
REVVITY, INC. passes 4 of 9 quality checks, suggesting mixed fundamentals.
REVVITY, INC. trades at 53.4x trailing earnings, compared to its 15-year median P/E of 29.8x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 24.2x vs a median of 25.8x. The company's 5-year average ROIC is 6.6% with a gross margin of 63.9%. Total shareholder yield (dividends + buybacks) is 6.4%. At current prices, the estimated annualized return to fair value is +7.1%.
REVVITY, INC. (RVTY) has a net profit margin of 8.4%. This is a modest margin.
REVVITY, INC. (RVTY) generated $509 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
REVVITY, INC. (RVTY) has a debt-to-equity ratio of 0.46. This indicates a conservatively financed balance sheet.
REVVITY, INC. (RVTY) reported earnings per share (EPS) of $2.07 in its most recent fiscal year.
REVVITY, INC. (RVTY) has a return on equity (ROE) of 3.2%. This indicates moderate shareholder returns.
REVVITY, INC. (RVTY) has a 5-year average gross margin of 63.9%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 17 years of financial data for REVVITY, INC. (RVTY), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
REVVITY, INC. (RVTY) has a book value per share of $62.22, based on its most recent annual SEC filing.
Based on recent SEC filings and earnings disclosures, Management is executing a transformational strategy to divest the lower-growth, lower-margin immunodiagnostics business in China by year-end 2026, which is expected to improve organic growth by approximately 100 basis points and enhance operating margins by approximately 30 basis points on a pro forma basis. The company anticipates continued strong performance in Life Sciences, particularly in China where the right products and market positioning are driving meaningful growth, while Diagnostics is expected to benefit from sustained momentum in reproductive health and newborn screening despite challenging global birth rate trends. Management expects AI-driven acceleration in scientific discovery to generate significant future demand for consumables, instruments, and software as customers utilize these offerings to validate new therapeutic compounds and biological targets, positioning the company well for robust margin expansion in the first half of 2027 as cost efficiency initiatives anniversary. The company remains prudent in near-term assumptions pending more sustainable signs of concrete improvement in pharma and academic customer spending, though recent signs of stronger biopharma funding and M&A activity suggest potential for market recovery beyond current guidance.
Based on recent SEC filings and earnings calls, REVVITY, INC. (RVTY) has provided the following forward guidance: Total Revenue: $2.81 billion–$2.84 billion (FY2026); Organic Growth: 3%–4% (FY2026); Adjusted Operating Margin: 28.4% (FY2026); Adjusted Earnings Per Share: $5.20–$5.30 (FY2026).